Development of outpatient antiviral cocktails against sars-COV-2 and other potential pandemic RNA viruses

Active Cooperative Agreement Awarded Last action

Award ID
U19AI171421
Recipient
Awarding agency
Obligated
$69,058,677

Award facts

Assistance listing
93.855 Allergy and Infectious Diseases Research
Completion date 99% complete
Originally
Place of performance
Palo Alto, CA 94305, USA

Award details come from USAspending.gov.

Description

As the agency reported it.

Abstract
The overall platform and objective of the stanford avidd center, "synerx," is to develop outpatient antiviral cocktails against sars-COV-2 and other potential pandemic RNA viruses. Thus, the goal of each of our 7 projects is to develop towards the clinic a novel direct-acting antiviral (DAA) with a distinct mechanism of action, so that they can be used alone and in combination with other agents-providing additive, and ideally synergistic antiviral activity. To maximize the achievement of this goal, we seek to create 3 scientific cores that will each provide critical expertise and resources: the structural biology core to offer critical insights into our projects' antiviral targets and mechanisms of action; the pandemic assistance core to ensure adequate access to facilities with the requisite biosafety and containment to safely develop our projects' antivirals against sars-COV-2 and other potential RNA pandemic viruses; and the translation accelerator core, in which is embedded the industry consultants consortium, (ICC) to provide the requisite translational resources, industry rigor and expertise to advance each project in a milestone and go/no-go driven fashion. The range of planned activities spans the translational spectrum, from innovative target discovery and lead identification, to lead optimization and IND-enabling activities. Our antiviral modalities include small molecules, nucleic acids, and protein therapeutics. Our lead programs have demonstrated proof- of-concept in vivo antiviral efficacy, with the potential to combat coronaviruses, as well as other RNA viruses of pandemic potential. These efforts will include: a) targeting highly conserved RNA structures in viral RNA genomes with locked nucleic acid (LNA) antisense oligonucleotide (ASO) and small molecule therapeutics; b) improving formulations and delivery methods for nucleic acid therapeutics, and targeting virus-derived circular rnas; c) selectively targeting viral envelopes antiviral peptides and peptoids; d) developing small molecule ligands of essential viral proteins that induce selective degradation of their protein targets; e) developing potent and selective inhibitors of essential proteases of sars-COV-2 and other RNA viruses; f) developing small molecule inhibitors of sars-COV-2 exonuclease to both promote lethal mutagenesis of the viral genome as well as enhance the antiviral efficacy of ribonucleoside analogs; g) developing small molecule inhibitors of sars-COV-2 NSP4's role in membrane-associated RNA replication. We will establish an administrative core to effectively manage and optimally support the above, and provide critical regulatory expertise. Finally, we will leverage avidd funding with institutional support, matching philanthropy and industry partnerships, and strategic relationships to maximize preclinical development and ensure successful clinical and commercial development of synerx's most promising lead molecules. Successful accomplishment of our aims will yield exciting synergistic outpatient antiviral cocktails for sars-COV-2 and other RNA viruses of pandemic potential.

Transactions

Action Obligated Date
Amendment $0
Amendment $0
Amendment $0
Amendment $0
Amendment $0
Amendment $0
Amendment $0
Amendment $0
Amendment $0
Amendment $0
Amendment $0
Original award $69,058,677
Show all 12

Subawards

Subrecipient Amount Awarded
University Of Georgia Research Foundation, Inc. Development of outpatient antiviral cocktails against SARS-CoV-2 and other potential pandemic RNA viruses. $120,415
University Of Connecticut Of particular importance to my participation in this AViDD application has been our work using structure-based drug design to target new pathways for direct… $121,875
The Regents Of The University Of California. San Francisco I have been working on virology for over 30 years. I have the expertise, leadership, and training necessary to carry out the proposed research project… $193,800
Hebrew University Of Jerusalem (The) Drugs are a critical component in our arsenal against viruses. However, their potential is hampered by two elements: lack of diversity of the viral target and… $216,000
Northeastern University Dr. Lori Ferrins will be the primary scientific contact for the synthetic and medicinal chemistry aspects of the project. She will be responsible for… $36,450
Israel Institute For Biological Research The aim of this project is to extend the viral pathogens available for screening against by the Stanford AViDD Center projects. We propose to test these… $215,991
The Governors Of The University Of Alberta The proposed project will support the SyneRx program by advancing the development of inhaled therapies that protect against respiratory viruses. Delivering… $216,000
Vitalant Mosquito transmitted chikungunya virus (CHIKV) has a high potential to cause a global pandemic. Infection with CHIKV causes debilitating recurring sever… $316,600
The Governors Of The University Of Alberta The proposed project will support the SyneRx program by advancing the development of inhaled therapies that protect against respiratory viruses. Delivering… $216,000
Nanyang Technological University "Our overall objective is to develop a new class of direct acting-antivirals (DAAs) that can specifically target viral HQYHORSHV EXW QRW KRVW FHOO… $573,480
The University Of Texas Health Science Center At San Antonio I am writing to confirm my most enthusiastic participation, as part of Project 6 in your proposal entitled “Development of outpatient antiviral… $139,443
Emory University Year 1. During the first year, the Dahlman Lab at Emory University will synthesize and purify nanoparticles, and characterize how these nanoparticles deliver… $629,400
University Of Connecticut Of particular importance to my participation in this AViDD application has been our work using structure-based drug design to target new pathways for direct… $293,020
University Of Connecticut Health Center The work described in the UCHC sub-budget will be performed in the Weller lab in E2052/2053 in the Department of Molecular Biology and Biophysics at Uconn… $52,804
Dana-Farber Cancer Institute, Inc. Docking and molecular dynamics simulations will be used to understand the ligand protein interaction and system plasticity. We will use the structural models to… $41,876
University Of Texas Medical Branch At Galveston With our fully established and well-characterized small animal models (e.g., BALB/c and transgenic mice) and the extensive preclinical experience for… $964,448
Stichting VU The Vrijiew Universiteit (VU) Amsterdam is pleased to participate in the Research Center "Development of outpatienr antiviral cocktails against SARS-CoV-2 and… $189,000
University Of Florida Dr. Disney and colleagues in his laboratory a UF Scripps Biomedical Research will complete the following series of studies, delineaed by Project. Project 1:… $425,500
University Of North Carolina At Chapel Hill Drs. Craig E. Cameron, Jamie J. Arnold, and their team a UNC will be responsible for the work proposed in Aim 1. The Cameron- Arnold laboratory has idenified 29… $807,007
The Regents Of The University Of California. San Francisco I have been working on virology for over 30 years. I have the expertise, leadership, and training necessary to carry out the proposed research project… $357,708
Northeastern University Dr. Lori Ferrins will be the primary scientific contact for the synthetic and medicinal chemistry aspects of the project. She will be responsible for… $143,550
Israel Institute For Biological Research The aim of this project is to extend the viral pathogens available for screening against by the Stanford AViDD Center projects. We propose to test these… $215,991
Hebrew University Of Jerusalem (The) Drugs are a critical component in our arsenal against viruses. However, their potential is hampered by two elements: lack of diversity of the viral target and… $216,000
The Governors Of The University Of Alberta The proposed project will support the SyneRx program by advancing the development of inhaled therapies that protect against respiratory viruses. Delivering… $216,000
Vitalant Mosquito transmitted chikungunya virus (CHIKV) has a high potential to cause a global pandemic. Infection with CHIKV causes debilitating recurring sever… $316,600
Show all 25

Quick answers

Who received award U19AI171421?

U19AI171421 was awarded to The Leland Stanford Junior University by National Institute of Allergy and Infectious Diseases (National Institutes of Health) on May 16, 2022.

How much is award U19AI171421 worth?

$69,058,677 has been obligated on U19AI171421.

On GovTribe

See this award's full record

  • Every transaction and subaward
  • The recipient's other awards and teaming partners
  • Similar grant awards
  • Ask GovTribe AI about this award
Try for free Login